In conclusion, the presented case highlights the potential efficacy of neoadjuvant chemoimmunotherapy in treating high-risk, basal-type ER+ErbB2- breast cancer, particularly in achieving pathological complete response. This evidence concerns the gene ERBB2 and breast carcinoma.